Transient down-regulation of beta1 integrin subtypes on kidney carcinoma cells is induced by mechanical contact with endothelial cell membranes by Jones, Jon et al.
Introduction
Renal cell carcinoma (RCC) is the most common
renal tumour and the third most common malignancy 
encountered in urological oncology. Metastasized 
RCC is generally fatal, despite conventional 
chemotherapy, radiotherapy and hormonal therapy.
Immunotherapy, with administration of interferons or
interleukin-2 has shown some promise, however,
the total response rate is only about 20% and the
treatment is occasionally associated with severe
adverse effects.
Novel treatment strategies are therefore eagerly
awaited. However, the complex mechanism of tumour
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dissemination is far from being completely under-
stood.Before potential drug targets can be identified,
it is obligatory to analyze those events, which are
related to RCC metastasis. Several reports docu-
ment that adhesion molecules of the integrin family
may be responsible for regulating tumour cell prolif-
eration, invasion and malignant progression.
Integrins are heterodimeric molecules formed by a
combination of an alpha integrin subunit with a mem-
ber of the beta subunit. Classification occurs on the
basis of their beta subunit, whereby the beta1 sub-
types are considered to be the prototype key media-
tors of tumour dissemination. They not only provide
the mechanical link between tumour cells, vascular
endothelium and extracellular matrix, but also medi-
ate intracellular signalling through integrin-associated
adaptor molecules.
Publications, which have focussed on alterations
of the integrin expression level during cancer pro-
gression, are contradictory. When sections of squa-
mous-cell carcinomas were examined by immunohis-
tochemistry, considerable variations in integrin
expression were observed, ranging from normal
expression of a particular integrin to a complete inte-
grin loss or even integrin over-expression both within
a single tumour and between tumours [1]. Studies
with breast cancer cells have demonstrated that
blocking of beta1-integrin receptors leads to the
reversion of the malignant phenotype, but re-expres-
sion of beta1 induced similar results [2, 3].Tawil and
co-workers observed increased beta1 integrin
expression in metastatic mammary carcinoma cells
[4], whereas the inhibition of motility and invasion of
the metastatic breast carcinoma cell lines was also
accompanied by an increased integrin expression
[5]. Finally, integrin beta1 up-regulation is supposed
to correlate with progression of prostate carcinoma,
although mRNA levels of beta1 were reduced in neo-
plastic compared to normal prostate tissues [6].
The unclear function of integrins is reflected in the
lack of data dealing with beta1 integrins in RCC.
Since the hematogenous phase of tumour dissemi-
nation is the rate-limiting step in the metastatic
process, we established a tumour-endothelium 
co-culture assay and explored beta1 integrin alterations
on several RCC cell lines before and after endothe-
lial cell contact.The paper presents evidence that the
interaction of RCC cells with human vascular
endothelial cells is coupled with a rapid and
reversible loss of beta1 integrin subtypes, notably,
alpha2, alpha3 and alpha5 integrins. We, further-
more, demonstrate that this process is accompanied
by a reduced focal adhesion kinase (FAK) expres-
sion, FAK activity and diminished binding of tumour
cells to matrix proteins. Further intracellular sig-
nalling components are altered in RCC cells after
contacting HUVEC membrane fragments, which alto-




Monoclonal antibodies were used, directed against pro-
teins indicated subsequently: Cell cycle proteins:
Cdk1/Cdc2 (IgG1, clone 1), Cdk2 (IgG2a, clone 55), Cdk4
(IgG1, clone 97), Cyclin A (IgG1, clone 25), Cyclin B (IgG1,
clone 18), Cyclin D3 (IgG2b, clone 1), Rb (IgG2a, clone 2),
Rb2 (IgG2a, clone 10), RBBP (IgG1, clone 12),
p70s6kinase (IgG1, clone 16) were purchased from BD
Biosciences (Heidelberg, Germany). Signal transduction
proteins: MEK1 (IgG2a, clone 25), MEK2 (IgG2a, clone
96), MEK5 (IgG1, clone 21), ERK1 (IgG1, clone MK12),
ERK2 (IgG2b, clone 33), panERK (IgG2a, clone 16),
p90Rsk (IgG2a, clone 78), 14-3-3 epsilon (IgM, clone 12),
JNK (IgG1, clone 37), phospho-specific JNK
(pT183/pY185; IgG1, clone 41), p38 (IgG1, clone 27),
phospho-specific p38 (pT180/pY182; IgG1, clone 30) were
obtained from BD Biosciences. PKC proteins: PKCalpha
(IgG2b, clone 3), PKCbeta (IgG2b, clone 36), PKCdelta
(IgG2b, clone 14), PKCepsilon (IgG2a, clone21), PKCiota
(IgG2b, clone23), PKClambda (IgG1, clone41), PKCtheta
(IgG1, clone 27), DGKtheta (IgG1, clone 24), RACK1 (IgM,
clone20) were from BD Biosciences. Integrin activation:
anti integrin-linked kinase (ILK; clone 3), anti focal adhe-
sion kinase (Fak; clone 77) and anti phospho-specific Fak
(pY397; clone 18) were derived from BD Biosciences. Anti-
beta-actin monoclonal antibody was obtained from Sigma
(Taufenkirchen, Germany).
Cell cultures
Kidney carcinoma Caki-I and KTC-26 cells were purchased
from LGC Promochem (Wesel, Germany). A498 were
derived from CLS (Heidelberg, Germany). Tumour cells
were grown and subcultured in RPMI 1640 medium
(Seromed, Berlin, Germany) supplemented with 10% FCS,
100 IU/ml penicillin and 100 µg/ml streptomycin at 37°C in
a humidified, 5% CO2 incubator.828 © 2007 The Authors
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Endothelial cells (HUVEC) were isolated from human
umbilical veins and harvested by enzymatic treatment with
chymotrypsin. HUVEC were grown in Medium 199 (Biozol,
Munich, Germany), 10% fetal calf serum (FCS; Gibco,
Karlsruhe, Germany), 10% pooled human serum (Blood
Bank of The German Red Cross, Frankfurt am Main,
Germany), 20 µg/ml endothelial cell growth factor
(Boehringer, Mannheim, Germany), 0.1% heparin (Roche,
Basel, Switzerland), 100 ng/ml gentamycin (Gibco) and 20
mM HEPES-buffer (Seromed, Berlin, Germany). Subcultures
from passages 2–4 were selected for experimental use.
Isolation of HUVEC plasma membranes
HUVEC were pooled and washed in cold STM buffer 
(0.25 M sucrose, 5 mM Tris, pH 8.0, 0.5 mM MgCl2),
minced and homogenized using a Dounce homogenizer.
Nuclei and cell debris were removed by centrifugation at
280   g for 5 min.The supernatant was saved and the pel-
let resuspended in 0.25 M STM using a Dounce homoge-
nizer. The suspension was again centrifuged as above.
First and second supernatants were combined and cen-
trifuged at 1500 x g for 10 min. The resulting pellets, con-
taining the plasma membrane fraction, were resuspended
in 0.25 M STM and adjusted to 1.18 g/cm
3 sucrose densi-
ty using 2 M sucrose in 5 mM Tris, pH 8.0, and 0.5 mM
MgCl2. Sucrose density was determined at room tempera-
ture with an Abbe refractometer. Samples were transferred
to ultracentrifuge tubes and overlaid with 0.25 M sucrose.
After centrifugation for 60 min at 82,000 x g in a Beckman
L5-65 centrifuge (SW 28 rotor), the pellicle at the interface was
collected and resuspended in sufficient 0.25 M sucrose to
obtain a density of 1.05 g/cm
3. Protein concentration was
determined by the method of Lowry using BSA as a stan-
dard. 100 µg protein/ml was used to activate tumour cells.
For western blot experiments, which required high mem-
brane yield, cell membranes were additionally prepared by a
method based on that of Hill et al. [7]. HUVEC were harvest-
ed by mechanical scraping, pooled, and lysed by repeated
freeze ( 147°C) -thawing (+37°C). The lysed cell mem-
branes were harvested by centrifugation at 10,000 g for
30min and stored in aliquots at  80°C prior to use. To
exclude cytosolic or nucleic contamination, beta-actin content
and GAPDH mRNA was evaluated by western blot or reverse
transcriptase-polymerase chain reaction (RT-PCR), respec-
tively, and compared to intact HUVEC as the positive control.
Tumour cell attachment to extracellular
matrix components
24-well plates were coated with collagen (Seromed; diluted
to 100 µg/ml in PBS), laminin (BD Biosciences; diluted to
50 µg/ml in PBS), or fibronectin (BD Biosciences; diluted to
50 µg/ml in PBS) overnight. Plastic dishes served as the
background control. Plates were washed with 1% BSA
(bovine serum albumin) in PBS to block non-specific cell
adhesion. Thereafter, 1 x 10
5 tumour cells/well (stimulated
with plasma membrane fragments for 4 hrs versus non-
stimulated) were added for 60 min. Subsequently, non-
adherent tumour cells were washed off, the remaining
adherent cells were fixed with 1% glutaraldehyde and
counted microscopically. The mean cellular adhesion rate,
defined by adherent cellscoated well adherent cellsbackground,
was calculated from five different observation fields.
Evaluation of integrin surface expression
Tumour cell monocultures were washed in blocking solu-
tion (PBS, 0.5% BSA) and then incubated for 
60 min at 4°C with FITC-or PE-conjugated monoclonal anti-
bodies anti-alpha1beta1 (Becton Dickinson; clone SR84),
anti-alpha2beta1 (Becton Dickinson; clone AK-7), anti-
alpha3beta1 (Becton Dickinson; clone C3II1), anti-
alpha4beta1 (Cymbus Biotechnology, Hofheim, Germany;
clone HP2I1), anti-alpha5beta1 (Cymbus Biotechnology;
clone SAM-1), or anti-alpha6beta1 (Becton Dickinson;
clone GOH3). Integrin expression of tumour cells was then
measured using a FACscan (Becton Dickinson; FL-1H or
FL-2H (log) channel histogram analysis; 1   10
4 cells/scan)
and expressed as mean fluorescence units (MFU). A
mouse IgG1-FITC or a mouse IgG-PE was used as an iso-
type control (Cymbus Biotechnology).
Alpha2, alpha3 and alpha5 expression dynamics was
evaluated in an RCC-HUVEC co-culture model. The 0.5  
10
6 tumour cells/well were added to a HUVEC monolayer
grown in a 6-well plate. After different time periods, tumour
cells were harvested by accutase treatment and washed in
blocking solution (PBS, 0.5% BSA). Cells were fixed with
100 µl fixation medium (Fix & Perm; Biozol-An der Grub
Bioresearch, Eching, Germany) and washed twice in block-
ing solution (PBS, 0.5% BSA). Subsequently, they were
incubated for 60 min at 4°C with 100 µl permeabilization
medium (Fix & Perm) together with the monoclonal anti-
body anti Factor VIII-associated antigen (Von Willebrand
factor; clone F8/86; Dako, Hamburg, Germany). Finally,
tumour cells were marked with monoclonal antibodies anti
alpha2, anti alpha3, or anti alpha5, and FACS analysis was 
carried out.
Confocal microscopy
Integrin alpha3 localization were analyzed on A498
tumour cells.In the monoculture assay, tumour cells wereJ. Cell. Mol. Med.Vol 11, No 4, 2007
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labelled with PE marked anti alpha3 monoclonal antibod-
ies. In the co-culture assay, tumour cells were added to
HUVEC for 60 min or 24 hrs. Non-adherent cells were
washed off thereafter. The remaining cells were stained
with FITC labelled anti factor VIII-associated antigen
monoclonal antibodies and with PE labelled anti-integrin
alpha3 monoclonal antibodies as described above. To
prevent photobleaching of the fluorescent dye, specimen
were embedded in an antifade reagent/mounting medium
mixture (ProLong
TM Antifade Kit, MoBiTec, Göttingen,
Germany) and mounted on slides. The slides were
viewed using a confocal laser scanning microscope
(LSM 10; Zeiss, Jena, Germany) with a plan-neofluar
x100/1.3 oil immersion objective.
mRNA expression of beta1 integrins
mRNA expression of beta1 integrins was evaluated by
reverse RT-PCR.Tumour cells were seeded in 50 ml culture
flasks (25 cm
2 growth area; Falcon Primaria, Becton
Dickinson) and cultured with or without HUVEC membrane
fragments. Total RNA was extracted by using RNeasy kit
(Qiagen, Hilden, Germany) and RNA samples were then
treated with 80 U/ml of Rnase-free Dnase I (Boehringer
Mannheim, Mannheim, Germany) for 60 min at 37°C, to
eliminate amplifiable contaminating genomic DNA.
Subsequently, samples were incubated for 10 min at 65°C
to inactivate Dnase. Complementary DNA was synthesized
from 1 µg of total RNA per sample with a 60 min incubation
at 42°C, using the Moloney murine leukaemia virus reverse
transcriptase (Invitrogen, Karlsruhe, Germany) and oligo-(dT)
priming (Boehringer Mannheim). Amplification was carried
out using gene specific primers and Platinum-Taq poly-
merase (Invitrogen) in a Mastercycler Gradient thermocy-
cler (Eppendorf, Hamburg, Germany). Reactions were 
performed in the presence of 0.5 µl cDNA, with an initial
incubation step at 95°C for 2 min. Cycling conditions con-
sisted of denaturation at 95°C for 30 sec, annealing at 60°C
for 30 sec and extension at 72°C for 30 sec over a total of
30 cycles. The reaction was completed by another 10 min
incubation step at 72°C. The specific sequences for sense
and anti-sense primers are as follows: alpha2: 5 -
GCATCTCAGAAGTCTGTTGCC-3  and 5 - CCTGTTGT-
TACCTTCAGGGAG-3 ; (335 bp); alpha3: 5 - TACGTGC-
GAGGCAATGACCTA-3  and 5 - TTTGGGGGTGCAGGAT-
GAAGCT-3; (306 bp); alpha5: 5 - CA GACTTTCTT-
GCAGCGG-3  and 5 - GAATGGGAGTCTGAAATTGG-3 ;
312 bp).Internal controls for the polymerase chain reaction
(PCR) reaction were performed by running parallel reaction
mixtures with the housekeeping gene GAPDH: 5 -ATC TTC
CAG GAG CGA GAT CC-3  and 5 -ACC ACT GAC ACG
TTG GCA GT-3  (509 bp).The PCR products were subject-
ed to electrophoresis in 1.5% agarose gel and visualized by
ethidium bromide.
Western blotting
Cell cycle, cell signalling and integrin activation proteins
were evaluated by Western blot analysis: A498 cell
lysates, prepared from unstimulated cells or after stimula-
tion with HUVEC plasma membrane fragments, were
applied to a 7 % polyacrylamide gel and electrophoresed
for 90 min at 100 V. The protein was then transferred to
nitrocellulose membranes. After blocking with non-fat dry
milk for 1 hr, the membranes were incubated overnight
with the respective antibodies listed above. HRP-conju-
gated goat-anti-mouse IgG or IgM (Upstate
Biotechnology, Lake Placid, New York; dilution 1:5000)
served as the secondary antibodies. The membranes
were briefly incubated with ECL detection reagent
(ECL
TM, Amersham) to visualize the proteins and
exposed to an x-ray-film (Hyperfilm
TM ECTM, Amersham).
Statistics
All experiments were performed 3–6 times. Statistical sig-
nificance was investigated by the Wilcoxon–Mann-
Whitney-U-test. Differences were considered statistically
significant at a P-value less than 0.05.
Results
Integrin beta1 expression pattern 
Beta1 integrin subtype expression was evaluated
on three kidney carcinoma cell lines. Alpha1,
alpha3 and alpha6 subtypes were labelled with PE,
and background fluorescence controlled by mouse
IgG-PE. Alpha2, alpha4 and alpha5 subtypes were
labelled with FITC and background fluorescence
controlled by using mouse IgG-FITC. Flow cytome-
try, depicted as FL-1H or FL-2H (log) channel his-
togram analysis, demonstrated the same integrin
surface pattern on A498, Caki-I and KTC-26 mono-
cultures (Fig. 1). Alpha3 subtypes were detected
most extensively on all cell lines and were, there-
fore, analyzed in detail in further studies. Alpha1,
alpha2 and alpha5 were expressed to a lower
extent, whereas alpha4 and alpha6 subtypes 830 © 2007 The Authors
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were not significantly elevated over the background
values. Out of the low expressed integrins, 
alpha2 and alpha5 subtypes were included in sub-
sequent experiments.
Interaction of tumour cells with 
HUVEC induces integrin down-regulation
To explore if integrins become altered in the course
of tumour cell attachment to HUVEC, we analyzed
integrin receptor expression on tumour cells in a co-
culture model. A498, KTC26 or Caki1 were added to
a HUVEC monolayer, and integrin expression on the
tumour cells was determined after different time
periods. Cell cultures were double stained using a
monoclonal antibody directed against the HUVEC
specific Factor VIII-associated antigen and mono-
clonal antibodies directed against the alpha integrin
of question. Dot plot quadrant analyses have then
been carried out to show Factor VIII-positive cell
populations (VIII+/alpha integrin+; VIII+/alpha inte-
grin-), which reflect HUVEC, and Factor VIII-negative
cell populations (VIII-/alpha integrin+; VIII-/alpha
integrin-) which reflect tumour cells (Fig. 2A; repre-
sentative for A498). Time-dependent FACscan (FL-
1H/FL-2H [log] channel) histogram analysis of
alpha2, alpha3 and alpha5 expression during the
process of tumour cell adhesion to HUVEC revealed
a strong down-regulation of integrin subtypes on
A498, KTC26 or Caki1 cells immediately after
attachment to HUVEC. This phenomenon was of
transient nature with a maximum 30–60 min after
tumour cell addition to HUVEC (Fig. 2B).
Expression and localization of alpha3 integrins
were visualized by con-focal laser-scanning
microscopy. In this context, alpha3 was distributed
homogenously along the cell membrane of A498 cells
in the monoculture system (Fig. 3A, arrows).
However, alpha3 became undetectable in tumour
cells in the co-culture model 60 min after they had
attached firmly to the HUVEC monolayer (Fig. 3B,
arrows).To discriminate HUVEC from A498, endothe-
lial cells were coloured green (VIII-FITC), whereas
A498 were coloured red (alpha3-PE). Twenty-four
hours after tumour cell attachment to HUVEC, A498
cell aggregates were visualized which started to
destruct the HUVEC integrity. According to the FACS
Fig. 1 FACS analysis of integrin beta1 subtype expression on Caki-I, KTC-26 and A498 tumour cells. Cells were washed in block-
ing solution and then stained with specific monoclonal antibodies as listed in Materials and methods.A mouse IgG1-FITC was used
as an isotype control for FITC conjugated antibodies. To evaluate background staining of PE conjugated antibodies, goat, anti-
mouse IgG1-PE was used. Fluorescence was analyzed using a FACScan flow cytometer, and a histogram plot was generated to
show FITC/PE-fluorescence. One from 6 independent experiments.J. Cell. Mol. Med.Vol 11, No 4, 2007
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data, alpha3 integrins were re-expressed in the late
phase of tumour cell adhesion and detected again
along A498 cell membranes (Fig. 3C, arrows).
Contact to HUVEC membranes is
responsible for integrin down-regulation
Reduced integrin expression seen in the tumour cell-
HUVEC co-culture system pointed to two options: A)
Interaction of tumour cells with endothelium may
evoke membrane triggered alterations of integrin
expression level, or B) Interaction of tumour cells
with endothelium may evoke the release of soluble
mediators which then modify integrin expression. To
address this question, A498 cells were treated with
isolated HUVEC membrane fragments for 60 min
and integrin expression was analyzed thereafter.
Data were compared to non-treated cells and to
tumour cells activated with supernatant taken from
HUVEC tumour cell co-cultures. Figure 4 demon-
strates distinct and significant integrin alpha2, alpha3
and alpha5 mRNA down-regulation when A498 were
exposed to isolated endothelial membranes for
60–120 min. This effect occurred transiently. Twenty-
four hours after contact induction, mRNA activity
increased again and was then similar to the activity
seen under control conditions. Fluorometry data
revealed that down-regulation of alpha3 and alpha5
subtypes on the A498 cell surface was caused by the
contact with endothelial membranes but not by the
cell culture supernatant.
Quantitative loss of integrins may not necessarily
be coupled with reduced receptor activity. We there-
fore explored ILK, FAK and phosphorylation of FAK
(pFAK), which are involved in the regulation of inte-
grin function. The experiments were carried out
before and after treatment of A498 cells with HUVEC
membrane fragments. Figure 5 demonstrates that
both FAK and pFAK was down-regulated in A498
cells in the presence of HUVEC membranes.
Integrin loss is attributed to diminished
adhesion capacity of tumour cells
Our data indicated that the adhesion of kidney carci-
noma cells to endothelium alters integrin alpha2,
Fig. 2 Down-regulation of alpha integrins on RCC cell lines co-cultivated with HUVEC. Cell cultures were double stained using the
HUVEC specific Factor VIII-associated antigen monoclonal antibody (clone F8/86) and monoclonal antibodies directed against
alpha2, alpha3 or alpha5 integrins. Both cell populations were defined in the FL-1 versus FL-2 dot blot diagram (Fig. 2A, represen-
tative for A498) and tumour cells (VIII-) analyzed separately. Dynamics of integrin expression is depicted in Fig. 2B as MFU values.832 © 2007 The Authors
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alpha3 and alpha5 expression. Integrin beta1 sub-
types are predominantly involved in cell adhesion to
the extracellular matrix. We consequently explored
whether heterogenous contact of tumour cells with
endothelial cell membranes leads to modified bind-
ing to the matrix proteins collagen, fibronectin or
laminin. In fact, pre-treatment of A498 cells with
endothelial membrane proteins was accompanied by
a reduced binding activity in the order laminin >
fibronectin > collagen (Fig. 6).
The relevance of alpha2, alpha3 and alpha5 inte-
grins for adhesion events was explored by blocking
studies using monoclonal antibodies. In this context,
adhesion of A498 cells to fibronectin, laminin, or col-
lagen was drastically inhibited by integrin blocking
antibodies (but not by the corresponding IgG isotype
control), which speaks for a link between integrin
down-regulation and blocking tumour cell-matrix
interaction (Fig. 6).
Intracellular signalling of tumour cells
is modified by HUVEC
Integrins serve as important downstream elements.
We therefore examined modifications of the intracel-
lular signalling cascade in A498 tumour cells before
and after exposure to isolated HUVEC membrane
fragments. The experiments concentrated on PKC
isoforms, the Mitogen-Activated Protein Kinase 
signalling pathway (MEKs, ERK, JNK, p38), and pro-
teins, which are involved in cell-cycle regulation
(cyclins, CDKs, Rb, p70s6kinase). Compared to the
controls, the addition of membrane proteins to
tumour cell cultures evoked down-regulation of
PKCdelta, PKCepsilon and PKClambda, whereas
PKCalpha, PKCbeta, PKCiota, PKCtheta remained
unchanged (Fig. 7). MEK1 and ERK1 became down-
regulated, whereas ERK2 was enhanced in the presence
of membrane proteins. JNK, p38 (total and activated)
Fig. 3 Confocal images of the distribution pattern of alpha3 integrin receptor molecules on A498 tumour cells. (A) shows distinct
alpha3 localization along the tumour cell surface in the monoculture model (arrows). (B) and (C) discriminate HUVEC from A498
in the co-culture model, specimen were stained against Factor VIII-associated antigen, labelled with FITC (green fluorescence),
and alpha 3 integrin, labelled with PE (red fluorescence). Overlay images of the red and green fluorescence channels are shown
in the right hand corner.Transmission pictures were taken to localize adherent tumour cells (arrow). Note that integrin alpha3 is lost
on adherent A498 cells after 60 min (B) but restored after 24 hrs (C).J. Cell. Mol. Med.Vol 11, No 4, 2007
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and RACK1 were reduced, however, 14-3-3 epsilon
was strongly elevated.
Expression level of cell cycle regulating proteins was
quantified additionally. Cyclin B and p70s6kinase were
both enhanced, RB and RB2 diminished in membrane
treated A498 cells, compared to the untreated controls.
Cyclin A, cyclin D3 and CDK subtypes were not altered
in treated versus non-treated cell cultures (Fig. 8).
Discussion
Beta1 integrin family members govern the adhesive
interactions between cancer cells and vascular
endothelium. Still, it is not clear which subtypes are
involved in RCC transmigration and how they 
contribute to this process.Our fluorescence analysis of
A498, Caki1 and KTC26 tumour cells revealed distinct
expression of alpha1, alpha2, alpha3 and alpha5
subtypes, whereas alpha4 and alpha6 subtypes
were not detected. Accordingly, RCC specimens
taken from metastatic tissue were all found to be
Fig.4 Endothelial membrane fragments but not cell culture supernatant reduce alpha3 and alpha5 surface expression and alpha2, alpha3
and alpha5 mRNA of A498 tumour cells. Surface level was analyzed by flow-cytometry and expressed as MFU values. *indicates signifi-
cant difference to controls (n = 6). RNA was extracted, reverse-transcribed and submitted to semi-quantitative reverse transcription-PCR
using gene-specific primers as described in Materials and methods.The internal control for the RT-PCR reaction was performed by run-
ning parallel reaction mixtures with the housekeeping gene GAPDH. One representative of three separate experiments is shown.
Fig. 5 Endothelial membrane fragments modulate focal adhe-
sion kinase (FAK) and FAK phosphorylation (pFAK) but not
integrin-linked kinase (ILK). Analysis was carried out by
Western blot technique. Cell lysates were subjected to SDS-
PAGE and blotted on the membrane incubated with specific
monoclonal antibodies (1:1000 dilution), listed in materials and
methods.  -actin served as the internal control. The figure
shows one representative from three separate experiments.834 © 2007 The Authors
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alpha2, alpha3 and alpha5 positive and alpha4 neg-
ative by immunohistochemistry, with a positive corre-
lation between integrin expression and tumour grad-
ing [8]. Different results have been presented in
another immunohistochemical study, where all inte-
grin alpha subtypes were present in RCC tissue
specimens, including alpha4, and where tumours of
higher grade showed decreased alpha3, alpha5 and
alpha6 expression [9].
Considering that only snapshots of expression are
provided in tissue analyses and that the same tech-
nique was applied in the above mentioned experiments,
dynamic and reciprocal alterations of the integrin
expression level at discrete stages of tumour metas-
tasis may be assumed which account for the
observed differences.We propose that not simply the
presence or absence of integrins may determine
cancer progression and grading, but transient recep-
tor modifications occur while RCC cells cross the
endothelial barrier. In fact, our in vitro experiments
present strong evidence that alpha2, alpha3 and
alpha5 integrins became down-regulated immediately
Fig. 6 Contact inhibition of A498. A498 cells were treated with endothelial membrane fragments or with monoclonal antibodies
directed against alpha2, alpha3 and alpha5 integrins (20µg/ml each). After preincubation, tumour cells were added to immobilized
collagen, laminin, or fibronectin. Adherent cells were counted after 60 min and mean values calculated (cells/mm2). *indicates sig-
nificant difference to controls One representative of 6 experiments is shown.J. Cell. Mol. Med.Vol 11, No 4, 2007
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after the tumour cells attached to the endothelial cell
monolayer followed by re-expression shortly there-
after. The rapid integrin turnover seems not to be a
unique phenomenon as the alphaVbeta5 receptor
down- and up-regulates in a short time span during
tissue morphogenesis [10, 11].
Integrin down-regulation on RCC cells was
caused by direct contact with endothelial cells, as
isolated endothelial membrane fragments but not cell
culture supernatant contributed to the observed
effects. We conclude that mechanical interaction is
the necessary precondition to allow integrin down-
regulation.However, it is not clear if integrins became
reduced after binding to their respective ligands on
endothelial cells or after binding to matrix proteins
exposed on endothelial cells. Because blocking
beta1 integrins did not influence attachment of
epithelial cancer cell lines to vascular endothelium
[12] but stopped tumour attachment to laminin
secreted by endothelial cells [13], it seems likely that
RCC integrins interact with extracellular matrix pro-
teins deposited on the endothelial cell monolayer,
rather than interacting with HUVEC.
The loss of alpha integrin subunits was accompa-
nied by a reduced FAK expression, FAK activity and
diminished binding of tumour cells to matrix proteins.
It is generally accepted that FAK promotes cell adhe-
sion, and in fact, integrin-stimulated cell adhesion
requires FAK and FAK activity [14]. However, cells
lacking FAK become refractory to motility signals
independent of integrin receptors [15]. Achiwa and
co-workers have speculated that continuous FAK
phosphorylation following tumour-matrix attachment
reflects decreased focal adhesion turnover and, con-
sequently, loss or down-regulation of FAK may be
necessary to maintain the malignant phenotype and
Fig. 7 Western blot analysis of intracellular signalling proteins, listed in materials and methods. A498 cells were treated with
endothelial membrane fragments for 60 min (control:untreated).Cell lysates were subjected to SDS-PAGE and blotted on the mem-
brane incubated with the respective monoclonal antibodies. Concentrations were as follows: 1:250: JNK (total and activated),
DGKtheta, PKCbeta, PKCtheta, PKCiota, PKClambda; 1:500: PKCdelta; 1:1000: 14-3-3 epsilon, MEK1, MEK5, p90RSK,
PKCalpha, PKCepsilon; 1:2500: MEK2, p38 (activated), RACK1; 1:5000: ERK1, ERK2, panERK, p38 (total). Beta-actin served as
the internal control. Bold types indicate changes to controls.The figure shows one representative from three separate experiments.836 © 2007 The Authors
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initiate tumour motility [16]. In line with this assump-
tion, dephosphorylation of FAK resulted in the loss of
adhesion signals and promoted enhanced tumour
migration in a breast carcinoma model [17]. It, there-
fore, seems plausible that the dynamics of tumour
transmigration are not always controlled by the FAK-
integrin pathway, but further regulatory proteins are
involved at a particular time.
Indeed, the conversion from beta1-integrin-
dependent movement to beta1-integrin-independent
single-cell motility has been observed recently on pri-
mary melanoma explants [18]. Accordingly, blocking
of beta1 integrins on RCC cells impaired binding to
extracellular matrix proteins but not polarized cell
movement [19, 20]. We propose that dynamic and
reversible alterations of the integrin profile play an
important part in tumour cell migration strategy,
switching the cells from being adhesive to becoming
motile and invasive [21]. No experiments have been
carried out dealing with this issue. However, MCF-7
breast cancer cell lines adhered less efficiently,
migrated more efficiently and became invasive when
FAK was dephosphorylated [22]. Transition from
adhesive interaction toward amoeboid locomotion
was initiated in melanoma and neural crest cells after
blocking beta1 integrins [18, 23].
In context with our experiments, the loss of inte-
grins may facilitate detachment of RCC cells from the
vasculature and promote dynamic movement and
spread into the target organ.We further conclude that
changes of the protein expression pattern may be
associated with this process. In fact, 14-3-3 epsilon
proteins that were amplified in our in vitro model were
recently demonstrated to force metastatic progres-
sion of breast or lung cancer [24, 25]. There is also
evidence that ERK2 contributes to enhanced tumour
motility and spread. Transendothelial migration of
monocytes as well as enhanced chemotactic activity
of neutrophils has been shown to be accompanied by
elevated ERK2 but not ERK1 levels [26, 27].This also
occurred in our co-culture assay, which points to the
specific involvement of the ERK2 isoform in RCC dis-
semination. PKCepsilon is linked to integrin beta
chains and to integrin-mediated cell adhesion in sev-
eral types of cancer [28, 29]. Down-regulation of
PKCepsilon in context with reduced beta1 subtype
expression may therefore underline the concept of
switching from integrin-dependent adhesion to inte-
grin-independent cell movement. We also found
reduced PKCdelta in RCC cells after treatment with
HUVEC membranes, process of which drives tumour
cells to become highly motile [30]. In accordance with
Fig. 8 Western blot analysis of cell
cycle proteins, listed in materials and
methods. A498 cells were treated
with endothelial membrane fragments
for 60 min (control: untreated). Cell
lysates were subjected to SDS-PAGE
and blotted on the membrane incu-
bated with the respective monoclonal
antibodies. Concentrations were as
follows: 1:250: CDK4, cyclin A, RB;
1:1000: p70s6kinase, cyclin B, cyclin
D3, RB2, RBBP; 1:2500: CDK1,
CDK2. Beta-actin served as the inter-
nal control. Bold types indicate
changes to controls.The figure shows
one representative from three sepa-
rate experiments.J. Cell. Mol. Med.Vol 11, No 4, 2007
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our observations down-regulation of RACK1 has
been recorded in a multicellular spheroid coculture
model of breast tumour cells and fibroblasts [31].This
is of particular importance as RACK1 has been
demonstrated to convert tumour cells from being
adhesive to becoming motile [17].
Nevertheless, although changes of the intracellu-
lar signalling cascade support our speculation of
switching the tumour cell migration strategy, we are
aware that the interpretation of the protein data is dif-
ficult. Numerous functions are ascribed to each sin-
gle protein and alterations of a particular protein may
not adequately reflect the dynamic interactions
between tumour and endothelium. Changes of the
protein profile as a total should be considered, which,
furthermore, may not exclusively be linked to adhesion
events. Although purely speculative integrin down-
regulation may also reflect tumour escape mecha-
nism by reducing immunoreactivity. Alterations of cell
cycle regulating proteins, which became evident in
our model, refer to modulations of the tumour cell
proliferation program.In fact, recent findings focus on
distinct alterations of tumour behaviour during vascu-
lar transmigration by diminishing their adhesive
forces and simultaneously elevating their proliferative
capacity [32, 33].
To sum up, we present evidence that the interac-
tion of RCC cells with human vascular endothelial
cells is coupled with a rapid and reversible loss of
beta1 integrin subtypes and integrin-dependent sig-
nalling. Hypothetically, RCC may alter the adhesive
strength of tumour-HUVEC and/or tumour-matrix
interactions, to undergo transition from one migration
program to another. Because cell migration may
comprise diverse cellular and molecular mecha-
nisms, future therapeutic targeting of the invasion
cascade will require taking such migratory plasticity
into consideration.
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